TNF and inflammatory bowel disease: Among the 34 included patients, 19 (61.3%) underwent monotherapy for IBD; corticosteroid therapy was administered in 10 cases (32.3%), TNF antagonist therapy in 6 cases (19.4%), ustekinumab therapy in 2 cases (6.4%), and mesalazine therapy in 1 case (3.2%).